#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14084	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2388	725.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1894	1894	T	875	T,G,C	872,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14084	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2388	725.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1628	1628	C	926	C	926	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14084	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2388	725.3	0	HET	.	.	.	C1269T	.	1269	1269	C	1713	1713	C	922	C,T	710,212	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23882	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4058	733.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1941	1941	A	976	A,G,C	974,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23882	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4058	733.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2575	2575	C	835	C,A,T	831,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23882	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4058	733.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2649	2649	A	758	A	758	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23882	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4058	733.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3201	3201	C	902	C,A	900,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2332	folP	852	852	99.88	folP.l15.c4.ctg.1	1951	148.9	0	.	p	.	0	E151K	NONSYN	451	453	GAA	984	986	AAA	232;230;226	A;A;A,G	232;230;225,1	.	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2332	folP	852	852	99.88	folP.l15.c4.ctg.1	1951	148.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1215	1217	AGC	224;229;227	A;G;C	224;229;227	folP.WHO_N_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5066	gyrA	2751	2751	99.89	gyrA.l15.c17.ctg.1	3890	162.7	0	.	p	.	0	K261del	DEL	781	781	A	1366	1366	A	197	A	196	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5066	gyrA	2751	2751	99.89	gyrA.l15.c17.ctg.1	3890	162.7	1	SNP	p	S91F	0	.	.	271	273	TCC	856	858	TCC	172;172;172	T;C;C	172;172;172	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5066	gyrA	2751	2751	99.89	gyrA.l15.c17.ctg.1	3890	162.7	1	SNP	p	D95G	0	.	.	283	285	GAC	868	870	GAC	184;188;188	G;A;C	184;188;188	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5066	gyrA	2751	2751	99.89	gyrA.l15.c17.ctg.1	3890	162.7	1	SNP	p	D95N	0	.	.	283	285	GAC	868	870	GAC	184;188;188	G;A;C	184;188;188	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1868	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1810	128.7	1	SNP	p	G45D	0	.	.	133	135	GGC	714	716	GGC	231;232;231	G,T;G,C;C	230,1;231,1;231	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1018	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1401	90.5	0	.	n	.	0	A197.	DEL	197	197	A	753	753	A	202	A	202	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4860	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3400	178.3	1	SNP	p	D86N	0	.	.	256	258	GAC	816	818	GAC	204;207;204	G,A;A;C	203,1;207;204	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4860	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3400	178.3	1	SNP	p	S87W	0	.	.	259	261	AGT	819	821	AGT	204;204;206	A,C;G;T	203,1;204;206	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4860	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3400	178.3	1	SNP	p	S87R	0	.	.	259	261	AGT	819	821	AGT	204;204;206	A,C;G;T	203,1;204;206	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4860	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3400	178.3	1	SNP	p	S87I	0	.	.	259	261	AGT	819	821	AGT	204;204;206	A,C;G;T	203,1;204;206	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4860	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3400	178.3	1	SNP	p	S88P	0	.	.	262	264	TCC	822	824	TCC	207;206;207	T;C,A;C	207;205,1;207	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4348	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3148	172.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1872	1874	GGC	254;249;249	G,T;G,A,T;C,G	252,2;247,1,1;248,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2722	178.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1402	1404	GCA	251;250;255	G,A,C;C;A	249,1,1;250;255	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2722	178.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1405	1407	ATC	256;256;256	A,C;T,C;C	255,1;255,1;256	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2722	178.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1417	1419	GTG	246;246;247	G,A;T,G;G	245,1;245,1;247	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2722	178.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1417	1419	GTG	246;246;247	G,A;T,G;G	245,1;245,1;247	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2722	178.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1921	1923	ACC	216;215;214	A;C;C	216;215;214	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2722	178.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1975	1977	GCG	224;223;222	G,T;C,A;G	223,1;222,1;222	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2722	178.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1975	1977	GCG	224;223;222	G,T;C,A;G	223,1;222,1;222	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2722	178.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2098	2100	GGC	234;234;232	G,C;G;C,T	233,1;234;231,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2722	178.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2107	2109	GGC	237;238;238	G,T;G;C	236,1;238;238	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3914	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2722	178.9	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2125	2127	CTG	245;245;246	C;T,C;G	245;244,1;246	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5438	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	3548	191.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1873	1875	CCG	218;221;220	C;C;G	218;221;220	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2354	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2258	129.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	754	754	C	184	C	184	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	23;25;27	T;T;A	23;25;27	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	51;51;51	C;A;T	51;51;51	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	D274G	NONSYN	820	822	GAT	62	64	GGT	51;51;51	G;G;T	51;51;51	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	51;51;51	T;A;C	51;51;51	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	244	porB1a	984	226	90.71	porB1a.l15.c17.ctg.2	374	25.3	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2742	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2071	165.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	730	732	GAA	241;240;242	G;A;A	241;240;242	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2742	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2071	165.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	1018	1020	GAT	222;222;223	G;A,G;T	222;221,1;223	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2742	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2071	165.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1141	1143	TCA	268;269;267	T,C;C;A	267,1;269;267	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2742	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2071	165.2	0	.	p	.	0	D212N	NONSYN	634	636	GAT	1252	1254	AAT	237;236;236	A;A,T,C;T,G,A	237;234,1,1;234,1,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2742	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2071	165.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1270	1272	GTC	218;218;219	G;T;C	218;218;219	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2742	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2071	165.2	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1282	1284	TCT	223;222;222	T;C;T	223;222;222	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2742	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2071	165.2	0	.	p	.	0	S295G	NONSYN	883	885	AGT	1501	1503	GGT	225;227;227	G;G,C;T	225;226,1;227	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2742	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2071	165.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1600	1602	GCA	261;259;259	G;C,A;A	261;258,1;259	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2742	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2071	165.2	1	SNP	p	G120K	1	.	.	358	360	AAG	976	978	AAG	216;218;219	A;A;G,A	216;218;218,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2742	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2071	165.2	1	SNP	p	D121N	0	.	.	361	363	GAC	979	981	GAC	217;219;217	G,C;A;C	216,1;219;217	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2742	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2071	165.2	1	SNP	p	A121D	1	.	.	361	363	GAC	979	981	GAC	217;219;217	G,C;A;C	216,1;219;217	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9340	rpoB	4179	4179	99.95	rpoB.l6.c30.ctg.1	5479	212.7	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2293	2295	AAT	235;237;239	A;A;T,G	235;237;238,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9340	rpoB	4179	4179	99.95	rpoB.l6.c30.ctg.1	5479	212.7	0	.	p	.	0	A1019V	NONSYN	3055	3057	GCC	3691	3693	GTC	208;212;209	G,T;T;CAAA,CAA	207,1;212;200,1	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1366	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1504	113.2	1	SNP	p	V57M	1	.	.	169	171	ATG	766	768	ATG	227;227;227	A;T;G	227;227;227	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
